Low-dose Aspirin Seen to Reduce Amyloid Aggregates in Mouse Brains, Study Shows

Low-dose Aspirin Seen to Reduce Amyloid Aggregates in Mouse Brains, Study Shows
Treatment with low-dose aspirin was found to reduce the amount of brain amyloid aggregates that researchers believe are a hallmark of Alzheimer's disease, according to a mouse study. These findings may open new therapeutic doors to prevent memory loss in Alzheimer’s patients. The study, “Aspirin induces Lysosomal biogenesis and attenuates Amyloid plaque pathology in a mouse model of Alzheimer's disease via PPARα,” was published in The Journal of Neuroscience. Acetylsalicylic acid, commonly known as aspirin, is one of the most frequently used drugs to manage inflammation, pain, and fever, and it is widely used to treat cardiovascular diseases. Previous studies have evaluated its protective effect in different disorders such as Parkinson's disease. High-dose aspirin users were found to exhibit better maintenance of cognitive functions and had reduced incidence of Alzheimer’s disease. While these studies suggest that aspirin may prevent neurotoxicity, its mode of action is still not fully understood. Rush University Medical Center researchers found that by treating the brain cells of Alzheimer's mice with aspirin they were able to promote the production of new lysosomes, small vesicles essential for
Subscribe or to access all post and page content.

One comment


    If I recall well, some clinical studies using NSAID like aspirin did not show any benefits in slowing down the progression of AD. My question is, are these results limited to transgenic mouse models? After all, we should not forget that all of the drugs that have failed clinical studies were allowed to go into the clinical phase because of the promising results obtained with the transgenic models.

Leave a Comment

Your email address will not be published. Required fields are marked *